Literature DB >> 11349961

Conversion of normal to malignant phenotype: telomere shortening, telomerase activation, and genomic instability during immortalization of human oral keratinocytes.

M K Kang1, N H Park.   

Abstract

Normal somatic cells terminate their replicative life span through a pathway leading to cellular senescence, which is triggered by activation of p53 and/or pRb in response to critically shortened telomere DNA. Potentially neoplastic cells must first overcome the senescence checkpoint mechanisms and subsequently activate telomerase to propagate indefinitely. Although telomerase activation is closely associated with cellular immortality, telomerase alone is not sufficient to warrant tumorigenicity. Environmental factors, including chemical carcinogens and viral infection, often contribute to aberrant changes leading to tumorigenic conversion of normal cells. Of particular importance in oral cancer development are tobacco-related chemical carcinogens and human papillomavirus (HPV) infection. To describe the molecular mechanisms by which these environmental factors facilitate the genesis of oral cancer, we first established an in vitro multistep oral carcinogenesis model by sequential exposure of normal human oral keratinocytes (NHOK) to "high risk" HPV and chemical carcinogens. Upon introduction of the HPV genome, the cells bypassed the senescence checkpoint and entered into an extended, but not immortal, life span during which telomere DNA continued to shorten. In a few immortal clones surviving beyond the crisis, we found a marked elevation of telomerase activity and stabilization of telomere length. Furthermore, the E6 and E7 oncoproteins of "high risk" HPV disrupted the cell cycle control and DNA repair in immortalized HOK, and enhanced mutation frequency resulting from genomic instability. However, HPV infection alone failed to give rise to a tumorigenic cell population, which required further exposure to chemical carcinogens in addition to HPV infection. Analysis of the data presented suggests that oral carcinogenesis is a series of discrete genetic alterations that result from a continued genotoxic challenge by environmental risk factors. Our in vitro model may be useful for investigators with interest in furthering our understanding of oral carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349961     DOI: 10.1177/10454411010120010301

Source DB:  PubMed          Journal:  Crit Rev Oral Biol Med        ISSN: 1045-4411


  5 in total

1.  TNFα enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells.

Authors:  Sung Hee Lee; Hannah S Hong; Zi Xiao Liu; Reuben H Kim; Mo K Kang; No-Hee Park; Ki-Hyuk Shin
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

2.  miR-448 downregulates MPPED2 to promote cancer proliferation and inhibit apoptosis in oral squamous cell carcinoma.

Authors:  Linhan Shen; Liu Liu; Liangyu Ge; Long Xie; Siyu Liu; Lei Sang; Tiantian Zhan; Hongwei Li
Journal:  Exp Ther Med       Date:  2016-09-05       Impact factor: 2.447

3.  [Addiction to tobacco and the consequences for the skin].

Authors:  M Krug; A Wünsche; A Blum
Journal:  Hautarzt       Date:  2004-03       Impact factor: 0.751

Review 4.  Disruptive chemicals, senescence and immortality.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Hiroshi Kondoh; Matilde E Lleonart; Juan Fernando Martinez-Leal; Chiara Mondello; A Ivana Scovassi; William H Bisson; Amedeo Amedei; Rabindra Roy; Jordan Woodrick; Annamaria Colacci; Monica Vaccari; Jayadev Raju; Fahd Al-Mulla; Rabeah Al-Temaimi; Hosni K Salem; Lorenzo Memeo; Stefano Forte; Neetu Singh; Roslida A Hamid; Elizabeth P Ryan; Dustin G Brown; John Pierce Wise; Sandra S Wise; Hemad Yasaei
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  Differential mRNA expression profiling of oral squamous cell carcinoma by high-throughput RNA sequencing.

Authors:  Liangyu Ge; Siyu Liu; Long Xie; Lei Sang; Changyan Ma; Hongwei Li
Journal:  J Biomed Res       Date:  2015-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.